HomeAI · summaries
Storia in 13 fonti
FDA approves Lipfendra, the first oral PCSK9 inhibitor, to lower LDL
Merck and the FDA announced the approval of enlicitide 20 mg as an add-on to diet and exercise to lower LDL in adults with hypercholesterolemia and those with heterozygous familial hypercholesterolemia.Enlicitide (Lipfendra), a novel macrocyclic peptide, is the first oral PCSK9 inhibitor FDA-approved to lower LDL, according to press releases from the company and the FDA.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Merck wins first approval of a PCSK9 cholesterol pill
The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former commissioner Marty Makary.
- ·
healio.com
FDA approves Lipfendra, the first oral PCSK9 inhibitor, to lower LDL
Merck and the FDA announced the approval of enlicitide 20 mg as an add-on to diet and exercise to lower LDL in adults with hypercholesterolemia and those with heterozygous…
